Nunzia Prencipe1, Irene Floriani2, Federica Guaraldi1, Stellina V Di Giacomo1, Salvatore Cannavo3, Giorgio Arnaldi4, Alessandro Berton1, Valter Torri2, Maurizio Spinello5, Emanuela Arvat6, Ezio Ghigo1, Silvia Grottoli1. 1. Department of Medical Science, Division of Endocrinology, Diabetology and Metabolism, Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy. 2. Department of Oncology, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy. 3. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. 4. Endocrinology Division, Department of Clinical and Molecular Sciences, Politecnica delle Marche University, Ancona, Italy. 5. Novartis Farma, Origgio (VA), Italy. 6. Department of Medical Science, Division of Oncological Endocrinology, Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
Abstract
OBJECTIVE: Acromegaly, a disease caused by GH/IGF-I hypersecretion, is associated with a high mortality rate; early recognition is therefore necessary to ensure successful treatment and to avoid comorbidities. We have created a symptom/sign scoring tool (ACROSCORE) for physicians to use to identify acromegaly. DESIGN: To compare cases of acromegaly diagnosed between 1990 and 2014 against a control group affected by non-GH-secreting pituitary tumours to identify symptoms and signs that are most discriminative for acromegaly. PATIENTS: Confirmed acromegaly patients and patients affected by non-GH-secreting pituitary tumours. MEASUREMENTS: In all patients, signs, symptoms and comorbidities were recorded from medical records and collected using a specifically designed questionnaire. RESULTS: A total of 194 acromegaly patients [115 women; mean (SD) age 47·2 (14·2) years] and 243 patients affected by non-GH-secreting pituitary tumours [131 women; mean (SD) age 45·8 (15·8) years] were included. A strong association was observed for type 2/secondary diabetes [odds ratio (OR) 3·7], hyperhidrosis (OR 6·1), thyroid hyperplasia (OR 13·9), colorectal polyps (OR 10·4), spaced teeth (OR 25·4) and carpal tunnel syndrome (OR 4·3). Based on this information, a multivariable logistic model was built and a 14-point scoring system developed. A score of 0 excludes the risk of acromegaly [positive predictive value (PV(+)) = 0·6%]; scores 1-5 comprise a grey area; scores >5 indicate that a diagnosis of acromegaly cannot be excluded (PV(+) = 46·1%). CONCLUSIONS: Once validated in independent studies, ACROSCORE may represent a new tool for the clinical screening of acromegaly that can be used by general practitioners and nonendocrinology specialists.
OBJECTIVE:Acromegaly, a disease caused by GH/IGF-I hypersecretion, is associated with a high mortality rate; early recognition is therefore necessary to ensure successful treatment and to avoid comorbidities. We have created a symptom/sign scoring tool (ACROSCORE) for physicians to use to identify acromegaly. DESIGN: To compare cases of acromegaly diagnosed between 1990 and 2014 against a control group affected by non-GH-secreting pituitary tumours to identify symptoms and signs that are most discriminative for acromegaly. PATIENTS: Confirmed acromegalypatients and patients affected by non-GH-secreting pituitary tumours. MEASUREMENTS: In all patients, signs, symptoms and comorbidities were recorded from medical records and collected using a specifically designed questionnaire. RESULTS: A total of 194 acromegalypatients [115 women; mean (SD) age 47·2 (14·2) years] and 243 patients affected by non-GH-secreting pituitary tumours [131 women; mean (SD) age 45·8 (15·8) years] were included. A strong association was observed for type 2/secondary diabetes [odds ratio (OR) 3·7], hyperhidrosis (OR 6·1), thyroid hyperplasia (OR 13·9), colorectal polyps (OR 10·4), spaced teeth (OR 25·4) and carpal tunnel syndrome (OR 4·3). Based on this information, a multivariable logistic model was built and a 14-point scoring system developed. A score of 0 excludes the risk of acromegaly [positive predictive value (PV(+)) = 0·6%]; scores 1-5 comprise a grey area; scores >5 indicate that a diagnosis of acromegaly cannot be excluded (PV(+) = 46·1%). CONCLUSIONS: Once validated in independent studies, ACROSCORE may represent a new tool for the clinical screening of acromegaly that can be used by general practitioners and nonendocrinology specialists.
Authors: Alin Abreu; Alejandro Pinzón Tovar; Rafael Castellanos; Alex Valenzuela; Claudia Milena Gómez Giraldo; Alejandro Castellanos Pinedo; Doly Pantoja Guerrero; Carlos Alfonso Builes Barrera; Humberto Ignacio Franco; Antônio Ribeiro-Oliveira; Lucio Vilar; Raquel S Jallad; Felipe Gaia Duarte; Mônica Gadelha; Cesar Luiz Boguszewski; Julio Abucham; Luciana A Naves; Nina Rosa C Musolino; Maria Estela Justamante de Faria; Ciliana Rossato; Marcello D Bronstein Journal: Pituitary Date: 2016-08 Impact factor: 4.107
Authors: Alberto De Stefani; Francesca Dassie; Alexandra Wennberg; Giorgia Preo; Alice Muneratto; Roberto Fabris; Pietro Maffei; Antonio Gracco; Giovanni Bruno Journal: J Clin Med Date: 2022-02-18 Impact factor: 4.241
Authors: Elena V Varlamov; Dan Alexandru Niculescu; Swechya Banskota; Simona Andreea Galoiu; Catalina Poiana; Maria Fleseriu Journal: Endocr Connect Date: 2021-07-05 Impact factor: 3.335
Authors: M B Antsiferov; V S Pronin; T M Alekseeva; O A Ionova; E Y Martynova; Yu E Poteshkin; N A Chubrova; K Y Zherebchikova Journal: Probl Endokrinol (Mosk) Date: 2021-01-08